Lagevrio® (molnupiravir)

About Cleo Life Sciences

Founded in 2004, Cleo Life Sciences offers a unique hybrid model combining strategic CMC consulting with hands-on, small-scale laboratory prototyping to de-risk and accelerate pharmaceutical development. The company leverages its founder's deep industry experience, having contributed to the CMC development of five commercial drugs and over 60 clinical-stage candidates. Its mission is to transform pharmaceutical development by enabling earlier, faster, and more efficient product and process development for its biopharma clients.

About Ridgeback Biotherapeutics

Ridgeback Biotherapeutics is a private, clinical-stage biotech company specializing in antiviral therapeutics for high-need, emerging infectious diseases. Founded and led by healthcare investors Wendy and Wayne Holman, the company has successfully advanced two late-stage assets: the FDA-approved Ebola treatment EBANGA™ and the oral antiviral Lagevrio (molnupiravir) for COVID-19. Ridgeback's strategy centers on identifying and accelerating promising science for pathogens that are often overlooked by larger pharmaceutical players, positioning itself at the intersection of public health response and drug development. The company operates with a lean, virtual model, leveraging partnerships for development and commercialization.

Therapeutic Areas